ArticleCancer cell2018
A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment.
Open access · greenAbstract read
In one paragraph
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed, 1 pooled it
9.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
148 citing papers in PubMed, 1 synthesis or guideline pooled it, 258 citations in OpenAlex.
- Demystifying the potential of lipid-based nanocarriers in targeting brain malignancies.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- WAC is associated with malignant phenotypes and Wnt/β-catenin pathway activity in liver cancer cells.Translational cancer research · 2026Article
- Review
- Dissecting the aberrant vasculature of glioblastoma: mechanisms and therapeutic targets.Cancer metastasis reviews · 2026Review
- Oligodendrocyte transcription factor 2 orchestrates glioblastoma immune evasion by suppressing CXCL10 and CD8+ T cell activation.The Journal of clinical investigation · 2026Article
- Hyaluronan-Based Glioblastoma Tumor Constructs Maintain Patient Tumor Drug Responses and Genomic Parity.Micromachines · 2026Article
- Distinct molecular pathways leading to dosage-dependent temozolomide resistance in GBM stem cells.Cancer cell international · 2026Article
- Angiogenesis and Resistance Mechanisms in Glioblastoma: Targeting Alternative Vascularization Pathways to Overcome Therapy Resistance.Current pharmaceutical design · 2026Review
- Cancer cells metastasize in several types of cancer via two distinct routes, probably based on mechanical signals.Frontiers in cell and developmental biology · 2026Review
- Glia-derived VCAM1 promotes glioma progression.Frontiers in oncology · 2026Article
- Pericytes orchestrate a tumor-restraining microenvironment in glioblastoma.Nature communications · 2025Article
- Glioma tumor microenvironment and immunotherapy: past, present, and future.Biomarker research · 2025Review
- Keeping Wnt in check for efficient checkpoint blockade in glioblastoma.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Dual role of WNT10A in promoting the malignancy of glioblastoma and remodeling the tumor microenvironment.Neuro-oncology · 2025Article
- Synergizing photodynamic therapy and ethanol ablation: Light-activatable sustained-exposure ethanol injection technology for enhanced tumor ablation.Bioengineering & translational medicine · 2025Article
- Opportunities to Modulate Tumor Ecosystem Toward Successful Glioblastoma Immunotherapy.Cancer science · 2025Review
- Wnt7a can upregulate cell adhesion and migration related genes expression and facilitate the repair of corneal epithelial cells after injury.International ophthalmology · 2025Article
- Overexpressed Wnt-7a acts as a potential antitumor immune modulator and predicts poor prognosis in HNSCC.Heliyon · 2025Article
- Modulation of blood-tumor barrier transcriptional programs improves intratumoral drug delivery and potentiates chemotherapy in GBM.Science advances · 2025Article
88 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 10 institutions in 2 countries.
Amelie GriveauDepartment of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA; Eli and Edythe Broad Institute for Stem Cell Research and Regeneration Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Giorgio SeanoEdwin L. Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Samuel J SheltonEli and Edythe Broad Institute for Stem Cell Research and Regeneration Medicine, University of California San Francisco, San Francisco, CA 94143, USA; Department of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143, USA.
Robert KuppBarrow Neurological Institute, Saint Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA.
Arman JahangiriDepartment of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143, USA.
Kirsten ObernierEli and Edythe Broad Institute for Stem Cell Research and Regeneration Medicine, University of California San Francisco, San Francisco, CA 94143, USA; Department of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143, USA.
Shanmugarajan KrishnanEdwin L. Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Olle R LindbergDepartment of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143, USA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA.
Tracy J YuenDepartment of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA; Eli and Edythe Broad Institute for Stem Cell Research and Regeneration Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
An-Chi TienDepartment of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA; Eli and Edythe Broad Institute for Stem Cell Research and Regeneration Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Jennifer K SaboDepartment of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA; Eli and Edythe Broad Institute for Stem Cell Research and Regeneration Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Nancy WangEdwin L. Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Ivy ChenEdwin L. Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Jonas KloepperEdwin L. Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Louis LarrouquereEdwin L. Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Mitrajit GhoshEdwin L. Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Itay TiroshBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Emmanuelle HuillardICM Brain and Spine Institute, 47 Boulevard de l'Hopital, 75013 Paris, France.
Arturo Alvarez-BuyllaEli and Edythe Broad Institute for Stem Cell Research and Regeneration Medicine, University of California San Francisco, San Francisco, CA 94143, USA; Department of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143, USA.
Michael C OldhamDepartment of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143, USA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA.
Anders I PerssonDepartment of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143, USA; Department of Neurology, University of California San Francisco, San Francisco, CA 94143, USA; Sandler Neurosciences Center, University of California San Francisco, San Francisco, CA 94143, USA.
William A WeissDepartment of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA; Department of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143, USA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA; Department of Neurology, University of California San Francisco, San Francisco, CA 94143, USA.
Tracy T BatchelorStephen E. and Catherine Pappas Center for Neuro-Oncology, Department of Neurology and Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Anat Stemmer-RachamimovDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Mario L SuvàBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Joanna J PhillipsDepartment of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143, USA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA; Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA.
Manish K AghiDepartment of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143, USA.
Shwetal MehtaBarrow Neurological Institute, Saint Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA.
Rakesh K JainEdwin L. Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Electronic address: jain@steele.mgh.harvard.edu.
David H RowitchDepartment of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA; Eli and Edythe Broad Institute for Stem Cell Research and Regeneration Medicine, University of California San Francisco, San Francisco, CA 94143, USA; Department of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143, USA; Department of Pediatrics, University of Cambridge and Wellcome Trust-MRC Stem Cell Institute, Hills Road, Cambridge CB2 0AN, UK. Electronic address: dhr25@medschl.cam.ac.uk.
Harvard University · USNeurological Surgery · USMassachusetts General Hospital · USUniversity of California, San Francisco · USBroad Center · USBroad Institute · USSaint Joseph's Hospital · USSt. Joseph's Hospital and Medical Center · USUCSF Helen Diller Family Comprehensive Cancer Center · USWellcome/MRC Cambridge Stem Cell Institute · GB
Funding
Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Susan M Chang · 2002 to 2026
$57.4MVascular Normalization: Rolse of Perivascular CellsP01CA080124 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI · 2000 to 2016
$35.0MTargeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WENDY Beth LONDON · 2013 to 2026
$33.5MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2MRegulation of Cellular Pathwaysin Human Brain DevelopmentP01NS083513 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALVAREZ-BUYLLA, ARTURO · 2014 to 2024
$12.6MNEUROGENESIS IN THE ADULT VERTEBRATE BRAINR01NS028478 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALVAREZ-BUYLLA, ARTURO · 1996 to 2024
$8.6MTraining Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6MDissecting Pediatric Brain Tumor Microenvironment to Improve TreatmentR35CA197743 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2015 to 2020
$5.7MTumor cell and microenvironment changes causing antiangiogenic therapy resistanceR01NS079697 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGHI, MANISH · 2013 to 2021
$3.2MImproving the efficacy of mTOR inhibitionR01CA221969 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FAN, QI WEN, SHOKAT, KEVAN M. · 2018 to 2022
$2.9MCHARACTERIZATION OF NEURAL STEM CELLS IN THE ADULT BRAINR37NS028478 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALVAREZ-BUYLLA, ARTURO · 2000 to 2007
$2.9MPrecision Medicine For Pediatric Low-Grade GliomasR01NS091620 · NINDS · DANA-FARBER CANCER INST · PI HAAS-KOGAN, DAPHNE A., RESNICK, ADAM CAIN · 2015 to 2019
$2.6MMedical Research Council MC_PC_12009NCI NIH HHS P01 CA080124NCI NIH HHS P50 CA097257NCI NIH HHS P50 CA165962NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA208205NCI NIH HHS R01 CA221969NCI NIH HHS R35 CA197743NCI NIH HHS T32 CA151022NINDS NIH HHS P01 NS083513NINDS NIH HHS R01 NS028478NINDS NIH HHS R01 NS079697NINDS NIH HHS R01 NS081117NINDS NIH HHS R01 NS088648NINDS NIH HHS R01 NS091620NINDS NIH HHS R21 NS088114NINDS NIH HHS R37 NS028478Wellcome Trust
Abstract
Gliomas comprise heterogeneous malignant glial and stromal cells. While blood vessel co-option is a potential mechanism to escape anti-angiogenic therapy, the relevance of glial phenotype in this process is unclear. We show that Olig2
Indexed as
AnimalsBevacizumabBlood-Brain BarrierBrain NeoplasmsCell Line, TumorGene Expression Regulation, NeoplasticGliomaHumansMiceNeoplasm TransplantationOligodendrocyte Transcription Factor 2OligodendrogliaTemozolomideTumor Cells, CulturedTumor MicroenvironmentWnt ProteinsBevacizumabOLIG2 protein, humanOligodendrocyte Transcription Factor 2TemozolomideWNT7A protein, humanWNT7B protein, humanWnt Proteinsangiogenesisastrocyteblood-brain barriergliomainvasivenessOlig2oligodendrocyte precursorp53vessel co-optionWnt
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.